Cleocin HCl®
GoodRxClindamycin · oral capsule
Antibiotic
OFF-LABELNot in the FDA label for this product
Toxoplasmic retinochoroiditis, by intravitreal injection
1 mg clindamycin with 400 micrograms dexamethasone intravitreally, 1 to 3 injections. This is a compounded intravitreal preparation and NOT this oral capsule, which cannot be injected. Oral clindamycin's own role is as an alternative agent, usually substituted for sulfadiazine in sulfa-allergic patients, and that use has no randomised evidence behind it.
RCT n=68 · not this oral form
Read the route before the result. A randomised trial compared intravitreal clindamycin with dexamethasone against classic therapy, which in that trial was 6 weeks of pyrimethamine and sulfadiazine plus prednisolone and contained no clindamycin. Across 68 patients the primary endpoint did not separate the arms: lesions reduced 57.0% against 58.4% (p=0.569), so the finding is that the injection is an acceptable alternative rather than a better one, and 34 patients per arm cannot exclude a real difference either way. Nothing here tests the oral capsule this card describes.
Contraindications
CLEOCIN HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
Available Forms75 mg bottles, 150 mg bottles, 300 mg bottles
Mechanism of ActionClindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Warnings & Precautions
Anaphylactic and Severe Hypersensitivity Reactions: Anaphylactic shock and anaphylactic reactions have been reported (See ADVERSE REACTIONS ).
Common Side Effects
The following reactions have been reported with the use of clindamycin. Infections and Infestations: Clostridioides difficile colitis Gastrointestinal: Abdominal pain, pseudomembranous colitis, nausea, vomiting, and diarrhea (See BOXED WARNING ). The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (See WARNINGS ).
Pregnancy & LactationPregnancy: In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
Lactation: Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora.
Pediatric UseWhen CLEOCIN HCl is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.